I. Nankya

发表

Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort

P. Kaleebu, J. Weber, S. Beddows, 2007, Journal of acquired immune deficiency syndromes.

Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage

E. Arts, Richard Gibson, G. Nickel, 2015, AIDS Research and Therapy.

First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda

E. Arts, A. Poon, Richard Gibson, 2019, AIDS Research and Therapy.

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2016, The Journal of antimicrobial chemotherapy.

Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1

J. Bailey, T. Hope, Yong Gao, 2020, Journal of Virology.

Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure

E. Arts, Richard Gibson, M. Quiñones-Mateu, 2016, Antimicrobial Agents and Chemotherapy.

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV

N. Klein, F. Fitzgerald, A. Sarah Walker, 2019 .

Immune Responses in Ugandan Women Infected With Subtypes A and D HIV Using the BED Capture Immunoassay and an Antibody Avidity Assay

C. Morrison, Pai-Lien Chen, O. Laeyendecker, 2014, Journal of acquired immune deficiency syndromes.

Detection of novel HIV-1 drug resistance mutations by support vector analysis of deep sequence data and experimental validation

D. Lizotte, E. Arts, A. Poon, 2019, bioRxiv.

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

E. Arts, A. Poon, Richard Gibson, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis

K. Mandaliya, T. S. Boender, C. Kityo, 2022, AIDS.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates.

Yong Gao, E. Arts, Richard Gibson, 2009, BioTechniques.

Calculating HIV-1 infectious titre using a virtual TCID(50) method.

Yong Gao, E. Arts, I. Nankya, 2009, Methods in molecular biology.

Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.

T. F. Rinke de Wit, C. Kityo, R. Hamers, 2013, AIDS research and human retroviruses.

CCR5 promoter variants among Ugandan HIV-1 elite and viremic controllers: a laboratory ‑ based cross ‑ sectional study

O. J. Sande, Alex Kayongo, G. Mboowa, 2020 .

Genetic variations within the CCR5 promoter region among elite and viremic controllers in Uganda

O. J. Sande, Alex Kayongo, D. Kateete, 2020 .

Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection

C. Morrison, Pai-Lien Chen, C. Kwok, 2018, PLoS pathogens.

The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.

P. Easterbrook, E. Arts, S. Reynolds, 2009, AIDS reviews.

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda

C. Kato, I. Nankya, Fred Kyeyune, 2020, AIDS Research and Therapy.

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.

Peter Mugyenyi, Francis Ssali, Robert Colebunders, 2013, AIDS research and human retroviruses.

Hormonal Contraceptive Use and HIV Disease Progression Among Women in Uganda and Zimbabwe

C. Morrison, Pai-Lien Chen, E. Arts, 2011, Journal of acquired immune deficiency syndromes.

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Kishor Mandaliya, Wendy S Stevens, Raph L Hamers, 2011, The Lancet. Infectious diseases.

Towards a better understanding of exclusive breastfeeding in the era of HIV/AIDS: a study of prevalence and factors associated with exclusive breastfeeding from birth, in Rakai,Uganda.

R. Muwonge, I. Nankya, R. Ssenyonga, 2004, Journal of tropical pediatrics.

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial

M. Munjoma, W. Snowden, D. Gibb, 2016 .

Once vs twice-daily abacavir and lamivudine in African children

A. Walker, M. Munjoma, W. Snowden, 2016, AIDS.

Targets of Small Interfering RNA Restriction during Human Immunodeficiency Virus Type 1 Replication

Yong Gao, Measho H. Abreha, E. Arts, 2008, Journal of Virology.

Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa

C. Morrison, Pai-Lien Chen, C. Kwok, 2016, EBioMedicine.

HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle?

Yong Gao, E. Arts, D. Tebit, 2007, AIDS reviews.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2016, AIDS research and human retroviruses.

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance

T. F. Rinke de Wit, T. S. Boender, C. Kityo, 2016, Journal of tropical pediatrics.

Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

T. Quinn, M. Kamya, S. Reynolds, 2012, BMC Infectious Diseases.

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

T. F. Rinke de Wit, K. Mandaliya, T. S. Boender, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

E. Arts, A. Poon, Michael Crawford, 2017, Infectious Diseases of Poverty.

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

P. Easterbrook, K. Wools-Kaloustian, C. Kityo, 2017, Journal of acquired immune deficiency syndromes.

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

E. Arts, C. Kityo, B. Rodriguez, 2013, AIDS.

HIV-1 EVOLUTION: ROLE OF DIVERSITY AND FITNESS—IMPLICATIONS FOR THE EPIDEMIC

I. Nankya, 2010 .

CCR5- and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic

D. Katzenstein, E. Arts, C. Herrera, 2009, Journal of Virology.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

E. Arts, M. Quiñones-Mateu, C. Kityo, 2021, The Journal of antimicrobial chemotherapy.

Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.

C. Morrison, Pai-Lien Chen, O. Laeyendecker, 2015, AIDS research and human retroviruses.

Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda

J. Karn, W. Boom, D. Winner, 2022, Retrovirology.

Reduced CCR5 expression among Uganda HIV controllers

O. J. Sande, G. Mboowa, D. Kateete, 2023, Retrovirology.

Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women

C. Morrison, C. Kwok, E. Arts, 2015, Journal of the International Association of Providers of AIDS Care.

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

E. Arts, A. Poon, Richard Gibson, 2018, AIDS research and human retroviruses.